As of June 30, 2026, Drugs Made In America Acquisition II Corp. carries a market capitalization of 640.82M, placing it among publicly traded companies globally. Its enterprise value stands at 641.10M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 640.82M |
| Enterprise Value | 641.10M |
As of June 30, 2026, Drugs Made In America Acquisition II Corp. has 63.70M shares outstanding.
| Shares Outstanding | 63.70M |
As of June 30, 2026, Drugs Made In America Acquisition II Corp. trades at a trailing price-to-earnings ratio of 42.80.
| PE Ratio | 42.80 |
| PB Ratio | 1.29 |
| P/TBV Ratio | 1.29 |
| P/FCF Ratio | -435.00 |
| P/OCF Ratio | -435.00 |
As of June 30, 2026, Drugs Made In America Acquisition II Corp. maintains a current ratio of 0.34, meaning it holds 0.3x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.34 |
| Quick Ratio | 0.27 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | -0.32 |
These figures cover the twelve months ended June 30, 2026. The company generates approximately - - in revenue per employee across its workforce of 2.00, a quick read on workforce productivity versus industry peers.
| Employee Count | 2.00 |
These figures are as of the close on November 16, 2026. The 50-day moving average sits at 10.19, while the 200-day moving average is 10.07.
| 50-Day Moving Average | 10.19 |
| 200-Day Moving Average | 10.07 |
Over the twelve months ended June 30, 2026, Drugs Made In America Acquisition II Corp. generated - - in revenue and converted that into 13.02M in net income, yielding earnings per share of 0.24. EBITDA reached -1.42M, while operating income came in at -1.42M.
| Operating Income | -1.42M |
| Pretax Income | 13.02M |
| Net Income | 13.02M |
| EBITDA | -1.42M |
| EBIT | -1.42M |
| Earnings Per Share (EPS) | 0.24 |
As of June 30, 2026, Drugs Made In America Acquisition II Corp. holds 174,974.00 in cash and equivalents against 450,000.00 in total debt, resulting in a net debt position of 275,026.00. Total book value stands at 495.96M, with working capital of -426,751.00 providing operational flexibility.
| Cash & Cash Equivalents | 174,974.00 |
| Total Debt | 450,000.00 |
| Net Debt | 275,026.00 |
| Equity (Book Value) | 495.96M |
| Book Value Per Share | 7.79 |
| Working Capital | -426,751.00 |
Drugs Made In America Acquisition II Corp. produced -1.28M in operating cash flow over the twelve months ended June 30, 2026.
| Operating Cash Flow | -1.28M |
| Free Cash Flow | -1.28M |
| FCF Per Share | -0.02 |
These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -0.23: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -78.25, meaning Drugs Made In America Acquisition II Corp. raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -78.25 |
| FCF Yield | -0.23 |
As of June 30, 2026, Drugs Made In America Acquisition II Corp. has an Altman Z-Score of 21.13, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 21.13 |